The Legal Arguments Plaintiffs Claim: Manufacturers (Novo Nordisk, Eli Lilly) knew or should have known about risks of gastroparesis and NAION Warning labels failed to adequately disclose these serious side effects Drugs were aggressively marketed as safe and effective weight loss solutions without proper risk disclosure Patients would not have taken the medications had they known the true risks Defendants Respond: Claims are unfounded (Novo Nordisk statement) Will defend vigorously against lawsuits Motion to dismiss expected January 24, 2025 Argue that labels were adequate and that many conditions may be pre-existing or related to diabetes itself Whos Most at Risk
In the adapted strain (A 2 78), the expression levels of the hmgR and carRA genes have risen by 2 times and 1.5 times, respectively, compared to the parent strain (W78)
Tirzepatide slows gastric emptying, which can alter how quickly alcohol is absorbed and intensify its effects some patients find they feel the effects of alcohol more quickly and more strongly than they did before starting treatment
Farooq Anwar: Writing review & editing
Semaglutide occupies its receptors in the brain to suppress appetite and promote a feeling of fullness
If your current provider is unfamiliar with compounding, our guide on how to qualify for semaglutide and what to say when requesting GLP-1 options can help you navigate the conversation